PEXIDARTINIB HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for pexidartinib hydrochloride and what is the scope of patent protection?
Pexidartinib hydrochloride
is the generic ingredient in one branded drug marketed by Daiichi Sankyo Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pexidartinib hydrochloride has one hundred and thirty-five patent family members in forty-one countries.
One supplier is listed for this compound.
Summary for PEXIDARTINIB HYDROCHLORIDE
International Patents: | 135 |
US Patents: | 12 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Clinical Trials: | 17 |
Patent Applications: | 28 |
What excipients (inactive ingredients) are in PEXIDARTINIB HYDROCHLORIDE? | PEXIDARTINIB HYDROCHLORIDE excipients list |
DailyMed Link: | PEXIDARTINIB HYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PEXIDARTINIB HYDROCHLORIDE
Generic Entry Date for PEXIDARTINIB HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PEXIDARTINIB HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Daiichi Sankyo Co., Ltd. | Phase 2 |
Daiichi Sankyo, Inc. | Phase 4 |
Daiichi Sankyo Co., Ltd. | Phase 3 |
Pharmacology for PEXIDARTINIB HYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Slovenia | 3292123 | ⤷ Sign Up | |
Cyprus | 1115288 | ⤷ Sign Up | |
Taiwan | I805599 | ⤷ Sign Up | |
South Africa | 200903458 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | ⤷ Sign Up |
Japan | 2014088407 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREOF | ⤷ Sign Up |
European Patent Office | 2827904 | COMPOSÉS ET PROCÉDÉS POUR UNE MODULATION DE LA KINASE, ET INDICATIONS CORRESPONDANTES (COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.